Differential Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway in Acute Lymphoblastic Leukemia
Figure 1
Effect of ABL-directed tyrosine kinase inhibitors on BCR-ABL+ ALL LTCs.
Ph+ ALL cells with the T315I mutation showed no growth inhibition (A) or induction of cell death (B) in response to any of the TKI. The BCR-ABL+ ALL-LTC PH was used as a positive control (A and B).
Response to ABL-directed TKI of 6 non-mutated BCR-ABL+ LTCs (BV, CM, DW, KW, PH and VB) and the LTC KÖ with the T315I mutation (C). Cell death was examined on day 4 of exposure to increasing concentrations of imatinib, dasatinib, and nilotinib.
(A, B, C) Cell proliferation was assessed by XTT assay and induction of cell death was measured by Annexin-V/propidium iodide staining. The data shown represent the means + SD of 3 experimental replicates from one representative experiment out of 3 performed.